A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride

Figures & data

Table 1. Changes in IPSS, QoL, and OABSS with the DUT treatment in all patients.

	Mean ± SD
		Before DUT	3 months after DUT	6 months after DUT	12 months after DUT
IPSS total	16.6 ± 6.7	13.0* ± 6.6	12.4* ± 6.6	12.0* ± 5.9
Voiding subdomain	9.6 ± 4.9	7.2* ± 4.8	7.0* ± 5.0	6.9* ± 4.7
Storage subdomain	7.0 ± 2.9	5.7* ± 2.7	5.5* ± 2.6	5.1* ± 2.4
QoL	4.5 ± 1.2	3.9* ± 1.4	3.7* ± 1.5	3.5* ± 1.4
OABSS	6.2 ± 2.9	5.2* ± 2.4	5.1* ± 2.3	5.0* ± 2.2

IPSS; International Prostate Symptom Score, OABSS; Overactive Bladder Symptom Score, DUT; dutasteride, SD, standard deviation.

* p < 0.05 significantly different from before the dutasteride treatment.

Figure 1. Changes in IPSS (A) and OABSS (B) between patients with potency (triangle) and those with severe ED (circle) at baseline.

Figure 2. Changes in SHIM (A) and EHS (B) in 28 patients with potency at baseline.

Figure 3. Time course of ED severity according to SHIM in 28 patients with potency at baseline.

Table 2. Comparison of clinical characteristics between the deteriorated EF group and non-deteriorated EF group after 12 months of the DUT treatment.

			Deteriorated EF group	Non-deteriorated EF group	p values
Number			14	14
Age					0.450
		<70	8	6
		≥70	6	8
IPSS					0.131
		<20	5	9
		≥20	9	5
HT					0.357
		Yes	2	4
		No	12	10
DM					0.309
		Yes	0	1
		No	14	13
IHD					0.280
		Yes	1	3
		No	13	11
Mean ± SD before the DUT treatment
	SHIM		15.6 ± 4.8	15.9 ± 5.6	0.885
	EHS		2.6 ± 0.8	3.0 ± 1.1	0.346
	Free testosterone		8.6 ± 2.0	8.8 ± 3.4	0.884
	Testosterone		4.0 ± 0.9	4.0 ± 1.3	0.940
Deteriorated ED severity according to SHIM after 3 months of the DUT treatment
	Yes		11	1	<0.01
	No		3	13

EF; erectile function, IPSS; International Prostate Symptom Score, HT; hypertension, DM; diabetes mellitus, IHD; ischemic heart disease, SD; standard deviation, DUT; dutasteride, SHIM; Sexual Health Inventory for Men, EHS; erection hardness score.

Table 3. Baseline characteristics between patients anxious about ED and those who did not care about ED.

	Patients in the anxious about ED group	Patients do not care about ED group	p values
Number	18	10
Age	66.3 ± 6.6	72.1 ± 5.7	0.027
SHIM	17.2 ± 4.8	13.2 ± 4.8	0.043
EHS	3.2 ± 0.8	2.2 ± 1.0	0.010
Testosterone	4.07 ± 1.13	3.96 ± 1.17	0.820
Free testosterone	9.4 ± 2.8	7.5 ± 2.3	0.083
Prostate volume	51.4 ± 18.3	52.2 ± 20.3	0.921

ED; erectile dysfunction, SHIM; Sexual Health Inventory for Men, EHS; erection hardness score.